| Similar Articles |
|---|
 |
The Motley Fool
May 26, 2004
Charly Travers |
Elan and Biogen File for Approval There's a new multiple sclerosis drug on the horizon.   |
The Motley Fool
April 11, 2008
Brian Orelli |
Teva Tugs at Both Ends of the MS String Teva tries to get multiple sclerosis patients to switch to its drug. |
The Motley Fool
December 7, 2004
Charly Travers |
Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential. |
The Motley Fool
February 18, 2004
Jeff Hwang |
Elan's Early Submission Elan and Biogen Idec will submit a multiple sclerosis treatment ahead of schedule. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
July 26, 2006
Brian Lawler |
Biogen Slows Down Several potential growth drivers should help the biopharma. Ever since the merger with Idec, the company has been fairly well run (absent the Tysabri delays). Investors, take note. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
February 28, 2005
Charly Travers |
Another Drug Sector Shocker Patient death triggers voluntary withdrawal of MS drug Tysabri. Both BiogenIDEC and Elan have been rocked in trading today, down 41% and 68%, respectively, so far. |
The Motley Fool
October 22, 2008
Brian Orelli |
Biogen Has Growth in all the Wrong Places Biogen Idec saw substantial growth in the third quarter, but apparently it's coming from all the wrong places. |
The Motley Fool
November 1, 2006
Brian Lawler |
Biogen Idec's Booming Results Even with guidance for 2006 non-GAAP earnings per share raised to more than $2.20, Biogen shares are trading at a reasonable 24 times earnings, considering the level of scale and sales growth it has exhibited this year. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
The Motley Fool
February 8, 2005
Charly Travers |
Good Prognosis for Biogen IDEC Blockbuster products help the biotech firm continue its stellar performance. |
The Motley Fool
October 5, 2006
Brian Lawler |
Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up. |
The Motley Fool
January 12, 2010
Brian Orelli |
Tysabri: It's a Blockbuster! Yawn. So What? Is it really a big deal that Tysabri finally achieved blockbuster status? |
The Motley Fool
July 23, 2008
Brian Lawler |
No Picking at Biogen At a time in which all of its top drugs experienced at least double-digit percentage sales growth, there aren't many issues to poke at with Biogen Idec's just-released second-quarter financial results. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
January 16, 2008
Brian Lawler |
More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note. |
The Motley Fool
March 8, 2005
Charly Travers |
After the Crash, Is Biogen IDEC a Buy? Biogen stock plunge may be an overreaction to pulling multiple sclerosis drug Tysabri off the market. |
The Motley Fool
June 29, 2004
Charly Travers |
Antegren Gets Priority Review The FDA steps up the drug's time line for approval. |
The Motley Fool
January 25, 2010
Brian Orelli |
Tysabri Updates: All You Have to Do Is Ask Biogen Idec is willing to hook medical doctors up with an automatic monthly update of the number of progressive multifocal leukoencephalopathy cases for people taking it and Elan's multiple sclerosis drug, Tysabri. |
The Motley Fool
October 30, 2008
Brian Orelli |
Not What the Doctor Ordered Biogen reports a third case of a deadly brain disorder since their multiple sclerosis drug Tysabri made its return. |
The Motley Fool
July 24, 2007
Brian Lawler |
Biogen's Steady Growth Biogen reports another good quarter of growth, both top- and bottom-line. |
The Motley Fool
March 15, 2007
Brian Lawler |
Dueling Fools: Elan Bear How do you bring an Elan bear out of hibernation? Combine a crushing debt load, a huge cloud of uncertainty over its lead developmental drug program, and the launch of a new product that won't bring in enough revenue to sustain the current valuation, et voila! A bear is born. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
March 1, 2005
Stephen D. Simpson |
When Bad News Is Good News The withdrawal of Tysabri is terrible news for Biogen Idec and Elan, but other firms may benefit. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
March 1, 2006
Bill Mann |
Tysabri: As Bad as AIDS? A report on the Elan/Biogen drug gets blown out of proportion on the eve of an FDA review. To say that a lot rides on the outcome of this meeting for Elan shareholders is an understatement. |
The Motley Fool
March 26, 2009
Brian Orelli |
R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
February 28, 2008
Brian Lawler |
A Tysabri Heart Attack Biogen and Elan announce new warnings for multiple sclerosis drug Tysabri. |
The Motley Fool
October 1, 2009
Anders Bylund |
Why I'm Invested in Tysabri and Elan This Motley Fool analyst has investigated Elan both as an investor and a patient. What's his verdict on the company? |
Chemistry World
February 8, 2013
Andrew Turley |
Biogen buys Tysabri from Elan for $3.25bn US biotech Biogen Idec is to pay $3.25 billion to Irish drugmaker Elan for full rights to Tysabri (natalizumab) injections for the treatment of multiple sclerosis. |
The Motley Fool
March 11, 2005
Karl Thiel |
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? |
The Motley Fool
October 26, 2009
Brian Orelli |
For Tysabri, 23 Is 10 Too Many The side effect rate is important. |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
Elan Holds Its Ground Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands. If you're pinning your hopes on a full return on this drug, you might be signing on for more risk than you really want. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
The Motley Fool
April 25, 2008
Brian Lawler |
Biogen's Big Step Forward Pharmaceutical company Biogen IDEC boasts better results and a rosier outlook. |
The Motley Fool
February 22, 2011
Brian Orelli |
Biogen and Elan's Growing Problem More cases of potentially lethal PML. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
June 30, 2009
Brian Orelli |
Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
The Motley Fool
November 21, 2007
Brian Lawler |
Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
April 17, 2009
Brian Orelli |
When Revenue Trumps Earnings Biogen grows earnings, but what does that say about the future? |
